ISSN 0303-5212
 

Original Research 
RMJ. 2020; 45(3): 549-553


Comparison of 5 Fluorouracil and triamcinolone acetonide intralesional injection in the management of keloid

Hyder Ali, Madiha Siddique, Mujtuba Pervez, Suneel Kumar, Waqas Sami.

Abstract
Objective: To compare the effectiveness of intralesional 5-fluorouracil (5-FU) alone and in combination with triamcinolone acetonide (TAC) for treating keloids.
Methodology: This descriptive comparative study was conducted from June 2018 to February 2019 at Department of Plastic & Reconstructive Surgery, Dow University of Health Sciences and Dr. Ruth KM Pfau Civil Hospital, Karachi. Total 60 patients with keloid at different body part were randomly allocated into two groups. Group A was given 50mg/ml 5-FU intra-lesion while in Group B; in addition to 5-FU 50mg/ml (0.9 ml), 40 mg/ml triamcinolone acetonide (0.1 ml) was given intralesionally. The duration of treatment was 6 months during which injections were given at weekly intervals for four weeks, then twice a month for two months and then once a month until the keloid lesions in both groups assumed virtually the same level as that of surrounding tissue or for a maximum of 3 months.
Results: The mean age of the patients was 35.97±8.28 years. Efficacy was significantly higher in group B as compared to group A (p=0.020).
Conclusion: Patients who received intra-lesion 5-fluorouracil (5-FU) in combination with triamcinolone acetonide (TAC) showed better results in treatment of keloid as compared to 5- FU alone.

Key words: Keloids, intra-lesion 5-fluorouracil (5-FU), Intra-lesion triamcinolone acetonide.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Hyder Ali
Articles by Madiha Siddique
Articles by Mujtuba Pervez
Articles by Suneel Kumar
Articles by Waqas Sami
on Google
on Google Scholar

How to Cite this Article
Pubmed Style

Ali H, Siddique M, Pervez M, Kumar S, Sami W. Comparison of 5 Fluorouracil and triamcinolone acetonide intralesional injection in the management of keloid. RMJ. 2020; 45(3): 549-553.


Web Style

Ali H, Siddique M, Pervez M, Kumar S, Sami W. Comparison of 5 Fluorouracil and triamcinolone acetonide intralesional injection in the management of keloid. https://www.rmj.org.pk/?mno=75019 [Access: December 06, 2023].


AMA (American Medical Association) Style

Ali H, Siddique M, Pervez M, Kumar S, Sami W. Comparison of 5 Fluorouracil and triamcinolone acetonide intralesional injection in the management of keloid. RMJ. 2020; 45(3): 549-553.



Vancouver/ICMJE Style

Ali H, Siddique M, Pervez M, Kumar S, Sami W. Comparison of 5 Fluorouracil and triamcinolone acetonide intralesional injection in the management of keloid. RMJ. (2020), [cited December 06, 2023]; 45(3): 549-553.



Harvard Style

Ali, H., Siddique, . M., Pervez, . M., Kumar, . S. & Sami, . W. (2020) Comparison of 5 Fluorouracil and triamcinolone acetonide intralesional injection in the management of keloid. RMJ, 45 (3), 549-553.



Turabian Style

Ali, Hyder, Madiha Siddique, Mujtuba Pervez, Suneel Kumar, and Waqas Sami. 2020. Comparison of 5 Fluorouracil and triamcinolone acetonide intralesional injection in the management of keloid. Rawal Medical Journal, 45 (3), 549-553.



Chicago Style

Ali, Hyder, Madiha Siddique, Mujtuba Pervez, Suneel Kumar, and Waqas Sami. "Comparison of 5 Fluorouracil and triamcinolone acetonide intralesional injection in the management of keloid." Rawal Medical Journal 45 (2020), 549-553.



MLA (The Modern Language Association) Style

Ali, Hyder, Madiha Siddique, Mujtuba Pervez, Suneel Kumar, and Waqas Sami. "Comparison of 5 Fluorouracil and triamcinolone acetonide intralesional injection in the management of keloid." Rawal Medical Journal 45.3 (2020), 549-553. Print.



APA (American Psychological Association) Style

Ali, H., Siddique, . M., Pervez, . M., Kumar, . S. & Sami, . W. (2020) Comparison of 5 Fluorouracil and triamcinolone acetonide intralesional injection in the management of keloid. Rawal Medical Journal, 45 (3), 549-553.